Island Pharmaceuticals’ clinical milestone reported by The Australian
Australian antiviral developer Island Pharmaceuticals has successfully enrolled all participants in the Phase 2b therapeutic arm of its ISLA‑101 PROTECT clinical trial assessing a potential treatment for dengue fever. The completion of enrolment follows positive safety and antiviral activity signals from the Phase 2a arm and sets the stage for evaluating ISLA‑101’s impact on viral load and symptoms in infected subjects. High‑level results from the Phase 2b cohort were anticipated around April 2025, with full data to inform next steps in development. 
Island Pharmaceuticals’ clinical milestone reported by The Australian